Year: 2010 
Title: A randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (National Cancer Institute of Canada-Clinical Trials Group Trial, MA.12) 
Authors: Bramwell VHC;Pritchard KI;Tu D;Tonkin K;Vachhrajani H;Vandenberg TA;Robert J;Arnold A;O'Reilly SE;Graham B;Shepherd L; 
Reference: Annals of Oncology 2010 Feb ; 21 (2) 
Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2813306/?report=abstract 

Year: 2003 
Title: Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: A report from the National Cancer Institute of Canada Clinical Trials Group 
Authors: Crump M;Tu D;Shepherd L;Levine M;Bramwell V;Pritchard K; 
Reference: Journal of Clinical Oncology 2003 Aug 15; 21 (16) 
Link:  

Year: 2011 
Title: Measurement of Pax2, TC21,CCND1, and RFS1 as predictive biomarkers for outcomes in the NCIC CTG MA.12 trial of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer 
Authors: Basik M;Keilty D;Aleynikova O;Tu D;Li X;Shepherd LE;Bramwell V; 
Reference: Journal of Clinical Oncology 2011 Jun 3 ; 29 (suppl; abstr 560) 
Link: http://meetinglibrary.asco.org/content/82402-102 

Year: 2013 
Title: Expression of both Estrogen Receptor-beta 1 (ER-b1) and its co-regulator Steroid Receptor RNA Activator Protein (SRAP) are predictive for benefit from tamoxifen therapy in patients with Estrogen Receptor-alpha (ER-a)-Negative Early Breast Cancer (EBC) 
Authors: Yan Y;Li X;Blanchard A;Bramwell VHC;Pritchard KI;Tu D;Shepherd L;Myal Y;Penner C;Watson PH;Leygue E;Murphy LC; 
Reference: Annals of Oncology 2013 Aug 1 ; 24 (8) 
Link: http://annonc.oxfordjournals.org/content/early/2013/04/10/annonc.mdt132.abstract 

Year: 2013 
Title: Effect of continuous statistically standardized measures of estrogen and progesterone receptors on disease-free survival in NCIC CTG MA.12 Trial and BC Cohort 
Authors: Chapman JA;Nielsen T;Ellis M;Bernard P;Chia S;Gelmon K;Pritchard K;Maitre A;Goss P;Leung S;Shepherd L;Bramwell V; 
Reference: 2013 Aug 23; 15 (4) 
Link: http://breast-cancer-research.com/content/15/4/R71 

Year: 2013 
Title: RSF1 and Not Cyclin D1 Gene Amplification May Predict Lack of Benefit from Adjuvant Tamoxifen in High-Risk Pre-Menopausal Women in the MA.12 Randomized Clinical Trial 
Authors: Keilty D;Buchanan M;Ntapolias K;Aleynikova O;Tu D;Li X;Shepherd L;Bramwell V;Basik M; 
Reference: PLoS ONE 2013 Dec 19; 8 (12) 
Link: http://dx.doi.org/10.1371%2Fjournal.pone.0081740 

Year: 2018 
Title: The prognostic effects of somatic mutations in ER-positive breast cancer 
Authors: Griffith OL;Spies NC;Anurag M;Griffith M;Luo J;Tu D;Yeo B;Kunisaki J;Miller CA;Krysiak K;Hundal J;Ainscough BJ;Skidmore ZL;Campbell K;Kumar R;Fronick C;Cook L;Snider JE;Davies S;Kavuri SM;Chang EC;Magrini V;Larson DE;Fulton RS;Liu S;Leung S;Voduc D;Bose R;Dowsett M;Wilson RK;Nielsen TO;Mardis ER;Ellis MJ; 
Reference: 2018 Sep 4 ; 9 (1) 
Link: https://doi.org/10.1038/s41467-018-05914-x 

Year: 2019 
Title: Region-specific glucocorticoid receptor promoter methylation has both positive and negative prognostic value in patients with estrogen receptor-positive breast cancer 
Authors: Snider H;Villavarajan B;Peng Y;Shepherd LE;Robinson AC;Mueller CR; 
Reference: Clinical epigenetics 2019 Nov 1 ; 11 (1) 
Link: https://www.ncbi.nlm.nih.gov/pubmed/31675993